|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR1900021264 |
|
最近更新日期: Date of Last Refreshed on: |
2019-02-05 17:33:39 |
|
注册时间: Date of Registration: |
2019-02-05 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
基于高通量测序和代谢组学的银屑病患者肠道微生态研究 |
|
Public title: |
Genomics and metabolomic approach studying the diversity of gut microbiota in patients with psoriasis |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
基于高通量测序和代谢组学的银屑病患者肠道微生态研究 |
|
Scientific title: |
Genomics and metabolomic approach studying the diversity of gut microbiota in patients with psoriasis |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
张景展 |
研究负责人: |
康晓静 |
|
Applicant: |
Jingzhan Zhang |
Study leader: |
Xiaojing Kang |
|
申请注册联系人电话: Applicant telephone: |
+86 17799199675 |
研究负责人电话: Study leader's telephone: |
+86 13999927999 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
jzhzhang@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
drkxj666@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
新疆乌鲁木齐市天山区天池路91号 |
研究负责人通讯地址: |
新疆乌鲁木齐市天山区天池路91号 |
|
Applicant address: |
91 Tianchi Road, Tianshan District, Urumchi, Xinjiang |
Study leader's address: |
91 Tianchi Road, Tianshan District, Urumchi, Xinjiang |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
新疆维吾尔自治区人民医院 |
||
|
Applicant's institution: |
People’s Hospital of Xinjiang Uygur Autonomous Region |
||
|
研究负责人所在单位: |
|
||
|
Affiliation of the Leader: |
|
||
|
是否获伦理委员会批准: |
否/No |
||
|
Approved by ethic committee: |
No |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
伦理委员会批件附件: Approved file of Ethical Committee: |
||
|
批准本研究的伦理委员会名称: |
|
||
|
Name of the ethic committee: |
|
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2013-08-26 00:00:00 |
||
|
伦理委员会联系人: |
|
||
|
Contact Name of the ethic committee: |
|
||
|
伦理委员会联系地址: |
|
||
|
Contact Address of the ethic committee: |
|
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
新疆维吾尔自治区人民医院 |
||||||||||||||||||||||
|
Primary sponsor: |
People’s Hospital of Xinjiang Uygur Autonomous Region |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
新疆乌鲁木齐市天山区天池路91号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
91 Tianchi Road, Tianshan District, Urumchi, Xinjiang |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
科研经费 |
||||||||||||||||||||||
|
Source(s) of funding: |
Grants for Scientific Research |
||||||||||||||||||||||
|
Target disease: |
Psoriasis |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
病因学/相关因素研究 |
||||||||||||||||||||||
|
Study type: |
Cause/Relative factors study |
||||||||||||||||||||||
|
研究所处阶段: |
基础科学研究 | ||||||||||||||||||||||
|
Study phase: |
Basic Science |
||||||||||||||||||||||
|
研究设计: |
病例对照研究 |
||||||||||||||||||||||
|
Study design: |
Case-Control study |
||||||||||||||||||||||
|
研究目的: |
明确银屑病患者与健康对照组肠道菌群及粪便代谢物的组成和差异,阐明差异可能相关的代谢通路和合成途径。 |
||||||||||||||||||||||
|
Objectives of Study: |
Identify the composition and differences of gut microbiota and fecal metabolites in patients with psoriasis and healthy people. Elucidate the metabolic pathways and synthetic pathways that may be relevant for differences. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
病例组:根据赵辩的《临床皮肤病2010版》描述的有关典型银屑病表现的患者(激光扫描共聚焦显微镜或/和皮肤病理检查协助诊断),要求PASI 评分≥6 分,3 个月未内使用免疫抑制药物,如全身性皮质类固醇,甲氨蝶呤,环孢素或抗肿瘤坏死因子α,3 个月内未口服调节肠道菌群药物,2 周内未全身应用抗生素,且无肝硬化、肠道疾病和细菌感染。 |
||||||||||||||||||||||
|
Inclusion criteria |
Case group: According to Zhao Bian's "Clinical Skin Disease 2010 Edition", patients with typical psoriasis (laser scanning confocal microscopy or / and dermatological pathology to assist diagnosis), requiring PASI score ≥ 6 points, 3 months No immunosuppressive drugs, such as systemic corticosteroids, methotrexate, cyclosporine or anti-tumor necrosis factor alpha, have not been orally administered to the intestinal flora within 3 months, and no systemic antibiotics have been used within 2 weeks. No cirrhosis, intestinal diseases and bacterial infections. |
||||||||||||||||||||||
|
排除标准: |
排除患有自身免疫性疾病、肿瘤或遗传性疾病的人群。 |
||||||||||||||||||||||
|
Exclusion criteria: |
Exclude people with autoimmune diseases, tumors or hereditary diseases. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2019-06-01 00:00:00至 To 2021-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2019-06-01 00:00:00 至 To 2021-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
N/A |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
N/A |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
N/A |
|
Blinding: |
N/A |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
原始数据上传至发表学术刊物指定数据库 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Upload the original data to database of the scientific publication |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据收集采用CRF和EDC两种方式,保存于新疆维吾尔自治区人民医院。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data will be saved in People’s Hospital of Xinjiang Uygur Autonomous Region by using CRFand EDC. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |